# EDGAR Filing Document

**Accession Number:** 0001595855
**File Stem:** 0001493152-25-019719
**Filing Date:** 2025-10
**Character Count:** 15936
**Document Hash:** dd4c0d8297fcb89e940e66b3e14b6137
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-019719.hdr.sgml**: 20251027

**ACCESSION NUMBER**: 0001493152-25-019719

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20251027

**EFFECTIVENESS DATE**: 20251027

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Opaleye Management Inc.
- **CENTRAL INDEX KEY:** 0001595855

**ORGANIZATION NAME:**
- **EIN:** 205648796
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-15896
- **FILM NUMBER:** 251419596

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BOSTON PLACE
- **STREET 2:** SUITE 2600
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108
- **BUSINESS PHONE:** 617-904-9195

**MAIL ADDRESS:**
- **STREET 1:** ONE BOSTON PLACE
- **STREET 2:** SUITE 2600
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001595855

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Opaleye Management Inc.

**Address:** One Boston Place, Boston, MA 02108

**Telephone number:** 617-229-5085

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-15896

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 1

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                           | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                     | VOTE CATEGORY                              |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Acadia Pharmaceuticals, Inc              | 004225108 | 05/29/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                   | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |          78000 |                0 | FOR         |                                    78000 | FOR                         |  |
| Anaptysbio, Inc.                         | 032724106 | 06/17/2025     | To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials.                               | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |          98674 |                0 | FOR         |                                    98674 | FOR                         |  |
| Anika Therapeutics, Inc.                 | 035255108 | 06/20/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                           | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         490888 |                0 | FOR         |                                   490888 | FOR                         |  |
| Arvinas, Inc.                            | 04335A105 | 06/25/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                        | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        1890000 |                0 | AGAINST     |                                  1890000 | AGAINST                     |  |
| Avita Medical Inc.                       | 05380C102 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                        | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         420000 |                0 | For         |                                   420000 | FOR                         |  |
| Codexis Inc                              | 192005106 | 06/10/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                      | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        9560000 |                0 | FOR         |                                  9560000 | FOR                         |  |
| Disc Medicine, Inc.                      | 254604101 | 06/11/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                        | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         127585 |                0 | FOR         |                                   127585 | FOR                         |  |
| Edgewise Therapeutics Inc.               | 28036F105 | 06/13/2025     | Conduct an advisory vote on the compensation of our named executive officers.                                                                                        | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         480000 |                0 | FOR         |                                   480000 | FOR                         |  |
| ESSA Pharma Inc.                         | 29668H708 | 03/05/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                        | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        2209988 |                0 | AGAINST     |                                  2209988 | AGAINST                     |  |
| Evolus, Inc.                             | 30052C107 | 06/05/2025     | Approval of, on an advisory basis, the compensation of Evolus' named executive officers.                                                                             | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         140490 |                0 | FOR         |                                   140490 | FOR                         |  |
| Ginkgo Bioworks Holdings                 | 37611X209 | 06/12/2025     | Advisory vote to approve executive compensation.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         864719 |                0 | FOR         |                                   864719 | FOR                         |  |
| Gossamer Bio Inc                         | 38341P102 | 06/25/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.                                   | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        2904998 |                0 | For         |                                  2904998 | FOR                         |  |
| Harrow Inc.                              | 415858109 | 06/18/2025     | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as presented in the proxy statement.                         | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        3805000 |                0 | FOR         |                                  3805000 | FOR                         |  |
| Immunome Inc.                            | 45257U108 | 06/10/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                        | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        1245000 |                0 | FOR         |                                  1245000 | FOR                         |  |
| Kiniksa Pharmaceutical International PLC | G52694109 | 06/03/2025     | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.                                                                    | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |          60000 |                0 | FOR         |                                    60000 | FOR                         |  |
| Larimar Therapeutics, Inc.               | 517125100 | 05/13/2025     | Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers in 2024                                                                          | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         550000 |                0 | FOR         |                                   550000 | FOR                         |  |
| Liquidia Corporation                     | 53635D202 | 06/17/2025     | To approve, on an advisory basis, the compensation of our named executive officers.                                                                                  | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        2210000 |                0 | FOR         |                                  2210000 | FOR                         |  |
| Nurix Therapeutics, Inc                  | 67080M103 | 05/19/2025     | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.                         | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         147327 |                0 | FOR         |                                   147327 | FOR                         |  |
| Ocular Therapeutix Inc                   | 67576A100 | 06/11/2025     | To approve an advisory vote on named executive officer compensation.                                                                                                 | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        1595000 |                0 | FOR         |                                  1595000 | FOR                         |  |
| Opus Genetics, Inc.                      | 67577R102 | 04/30/2025     | Approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                           | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        1578947 |                0 | FOR         |                                  1578947 | FOR                         |  |
| Palvella, Inc.                           | 697947109 | 06/10/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                       | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         160000 |                0 | FOR         |                                   160000 | FOR                         |  |
| Protagonist Therapeutics, Inc.           | 74366E102 | 06/20/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                            | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         105000 |                0 | FOR         |                                   105000 | FOR                         |  |
| Protara Therapeutics                     | 74365U107 | 06/11/2025     | Approval, on an advisory basis, of the compensation of Protara Therapeutics, Inc.'s named executive officers, as disclosed in the proxy statement.                   | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        1725000 |                0 | FOR         |                                  1725000 | FOR                         |  |
| Rezolute, Inc.                           | 76200L309 | 12/05/2024     | To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers, or NEOs, as disclosed in the Executive Compensation section. | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         465000 |                0 | FOR         |                                   465000 | FOR                         |  |
| Rhythm Pharmaceuticals Inc               | 76243J105 | 09/18/2024     | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.                                                    | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         505000 |                0 | FOR         |                                   505000 | FOR                         |  |
| Rhythm Pharmaceuticals Inc               | 76243J105 | 06/24/2025     | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.                                                    | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         475000 |                0 | FOR         |                                   475000 | FOR                         |  |
| Sangamo Therapeutics, Inc.               | 800677106 | 06/12/2025     | To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as described in the accompanying Proxy Statement.                       | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        1850000 |                0 | FOR         |                                  1850000 | FOR                         |  |
| Stoke Therapeutics, Inc.                 | 86150R107 | 06/03/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                        | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         300000 |                0 | FOR         |                                   300000 | FOR                         |  |
| TG Therapeutics                          | 88322Q108 | 06/12/2025     | An advisory vote to approve the compensation of our named executive officers.                                                                                        | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         535000 |                0 | FOR         |                                   535000 | FOR                         |  |
| Trevi Therapeutics, Inc.                 | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.                          | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |         795000 |                0 | FOR         |                                   795000 | FOR                         |  |
| Zentalis Pharmaceuticals, Inc.           | 98954L105 | 06/17/2025     | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.                                                                    | SECTION 14A SAY-ON-PAY VOTES; COMPENSATION |        1910000 |                0 | For         |                                  1910000 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Opaleye Management Inc.

**By (Signature):** /s/ James Silverman

**By (Printed Signature):** /s/ James Silverman

**By (Title):** General Partner

**Date:** 10/27/2025